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Multiple drug (antibiotic) resistance (MDR) has become a major threat to the treatment of typhoid and other infectious diseases. 
Since the 1970s, this threat has increased in Salmonella enterica serovar Typhi, driven in part by the emergence of successful genetic 
clades, such as haplotype H58, associated with the MDR phenotype. H58 S. Typhi can express multiple antibiotic resistance determi-
nants while retaining the ability to efficiently transmit and persist within the human population. The recent identification of exten-
sively drug resistant S. Typhi only highlights the dangers of ignoring this threat. Here we discuss the evolution of the S. Typhi MDR 
phenotype and consider options for management.
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Since the introduction of antibiotics in the middle of the last 
century, there has been an increasing appreciation of the threat 
of antibiotic resistance [1, 2]. Following the first clinical use of 
penicillin, many other antibiotics have been introduced and, in 
each case, resistance has followed at some level. The threat of 
resistance has been compounded by a dramatic reduction in the 
rate of introduction of novel classes of antibiotics and an associ-
ated drop in investment in the area (https://amr-review.org). We 
are now in an era where the levels of circulating virulent, multi-
ple drug-resistant (MDR) bacteria threatens healthcare efficacy 
globally. Typhoid treatment was one of the key areas that imme-
diately benefited from antibiotic usage. This chronic infection 
with the potential for relapse, carriage, and complications was 
enormously challenging in terms of clinical management prior 
to antibiotics. Indeed, antibiotic treatment transformed the 
clinical management of the disease and the public’s percep-
tion of the threat the disease posed. Antibiotics, together with 
improved water treatment and better public health manage-
ment, led to the control of the disease, at least in economically 
developed settings. However, typhoid remains in economically 
deprived areas where poverty and poor infrastructure persisted 
[3]. In these same resource-limited settings, the indiscriminate 
use of antibiotics has encouraged resistance and selected for vir-
ulent MDR clades. Thus, antibiotic resistance in typhoid is now 
a clinical and economic challenge.
Salmonella enterica serovar Typhi (S. Typhi) is a subtype 
of the Gram-negative enteric pathogen Salmonella enterica. 
Unlike many other S.  enterica serovars, S. Typhi is a human 
restricted pathogen that, as far as we know, is propagated by 
human to human spread with no zoonotic reservoir and with a 
limited ability to survive longer term in the environment [4]. S. 
Typhi can persist in water and food contaminated with human 
fecal material, but there is no environmentally adapted stage of 
the bacterial life-cycle such as the formation of spores. The per-
sistence of S. Typhi in human populations is influenced by clin-
ically silent carriage within certain individuals (carriers) that 
can be infected for months and even years with periodic shed-
ding of S. Typhi into the environment in contaminated feces. 
Thus, antibiotic usage can influence both acute typhoid disease 
and the carrier state. In both states the emergence of antibiotic 
resistance is theoretically possible. Unlike other enteric bacte-
ria, genetic and phenotypic analysis (eg, through the controlled 
challenge of human volunteers) has indicated that S. Typhi is 
relatively poorly adapted for growth in the human intestine 
[5]. Indeed, many genes, for example, shdA associated with 
persistence in the intestine are inactivated in S. Typhi and are 
consequently known as pseudogenes [6]. S. Typhi also shows 
limited evidence of recombination with other bacteria, sug-
gesting the global population of S. Typhi is relatively isolated 
compared to other enteric bacteria that live free in the intes-
tine or environment [7]. This, theoretically, limits their relative 
ability to horizontally acquire genes, including those that are 
encoded on genetically mobile elements. Nevertheless, over 
the past 70 years, multiple antibiotic resistance in S. Typhi has 
emerged as a global threat.
THE EARLY EMERGENCE OF ANTIBIOTIC 
RESISTANCE IN S. TYPHI
Shortly after the introduction of chloramphenicol for the treat-
ment of typhoid, reports of resistance in S. Typhi began to 
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emerge [8]. These tended to be reports of sporadic resistance 
associated with clinical failures and because new antibiotics 
were being introduced on a regular basis, particularly in the 
1950–70s, this was largely regarded as a nuisance rather than 
a crisis. As S. Typhi has an unusual fastidious intracellular life-
style in vivo, some antibiotics worked much better than oth-
ers, and chloramphenicol became one of the “go to” antibiotics 
for this disease. The potential side effects of chloramphenicol 
dampened this enthusiasm to some extent, but cheaper antibi-
otics continued to be favored in resource-poor settings.
During the 1960s, resistance to 3 or more first-line (mul-
tiple) antibiotics including ampicillin, trimethoprim-sulfa-
methoxazole, and chloramphenicol, known as MDR, became 
more common, and MDR S. Typhi began to be reported more 
frequently. In 1972 a large MDR typhoid epidemic, with over 
10 000 reported cases, occurred in Mexico City and other parts 
of Mexico [9, 10]. The epidemic S. Typhi commonly exhibited 
resistance to chloramphenicol, tetracycline, streptomycin, and 
sulphonamides and encoded an R factor plasmid that was trans-
ferable to Escherichia coli. Some S. Typhi isolates from the epi-
demic also encoded resistance to ampicillin and/or kanamycin, 
but fortunately these never became dominant. Eventually, this 
epidemic subsided and remained a local phenomenon confined 
largely within Mexico. Other sporadic cases of MDR S. Typhi 
were reported in different countries over the next 2 decades, but 
these also did not become dominant.
MDR S. TYPHI BECAME A THREAT TO TREATMENT
During this period (1970–90) typhoid frequently occurred in 
regions with limited facilities for culturing S. Typhi and con-
sequently the levels of MDR remained largely unreported and 
likely underappreciated. However, the Wellcome Trust and 
Oxford University established a Clinical Unit in Ho Chi Minh 
City in Vietnam in conjunction with the Vietnamese govern-
ment, and a local program of typhoid surveillance involving 
blood culture and antibiotic susceptibility testing was estab-
lished. It quickly became clear that MDR was associated with 
up to 90% of the typhoid cases in Ho Chi Minh City and in 
a rural study area in the Mekong Delta [11]. This, in part, 
explained a high level of clinical relapse, intestinal perforation, 
and poor response to treatment. Other reports coming in from 
elsewhere, including India [12], resulted in a rethink about the 
treatment of typhoid, and the use of fluoroquinolones in the 
form of ciprofloxacin was advocated [13]. To that point, the 
use of fluoroquinolones in children was not common due to 
reported side effects associated with joint/cartilage damage. 
Nevertheless, the present threat of MDR encouraged ethically 
supported trials of ciprofloxacin in the treatment of typhoid, 
and this was reported as being very effective with a low level 
of clinical relapse. However, within a few years of the intro-
duction of ofloxacin treatment, S. Typhi exhibiting significant 
resistance to quinolones (nalidixic acid) and intermediate lev-
els of resistance to ofloxacin were reported in the same region 
[14]. The targets of fluoroquinolones are the DNA gyrase 
subunits encoded by genes gyrA and gyrB, as well as DNA 
topoisomerase IV components parC and parE. “Signature” 
mutations including those at codon positions 83 and 87 in the 
gyrA gene sequence are associated with resistance. These sig-
nature mutations were identified in the nalidixic acid resistant 
derivatives of S. Typhi in Vietnam [15].
Over the next decade, the use of ciprofloxacin for the treat-
ment of typhoid, and indeed other infections, became wide-
spread across parts of Asia, and the reports of resistance began 
to increase in general frequency.
THE EMERGENCE OF MDR CLADES OF S. TYPHI
As part of the studies on MDR S. Typhi in Vietnam, work was 
initiated to use molecular approaches including pulse field gel 
electrophoresis (PFGE) to characterize the S. Typhi and start to 
understand the population structure of the pathogen. An aim 
here was to try to track transmission and identify outbreaks in 
a region with a high level of endemic disease. It was quickly 
noted that the PFGE patterns of S. Typhi isolated before 1990 
were diverse, but those isolated after this time onward became 
increasingly conserved as one PFGE type [16]. S. Typhi itself 
is highly clonal compared to many other pathogens, and this 
characteristic confounded the epidemiological investigations. 
This observation remained of interest, but the limitations of 
the techniques meant that this phenomenon remained unex-
plained. However, it was noted that all MDR S. Typhi harbored 
a large, transferrable R factor of incompatibility group IncHI1, 
the same group as the plasmid identified in Mexico in 1970 [17].
Over the next years, the interest in bacterial population 
structures increased as the technologies advanced. Techniques 
such as multi locus sequence typing (MLST) were invented, but 
they were not sufficiently discriminatory to provide further res-
olution of the population structure of S. Typhi, which is largely a 
single MLST type. Further advances into molecular typing using 
rare single nucleotide polymorphisms in the bacterial genome 
were eventually developed and applied to a global collection 
of S. Typhi [7]. These studies identified an emerging subtype, 
known as a haplotype, of S. Typhi designated H58 that was as-
sociated with both MDR and fluoroquinolone resistance signa-
ture mutations in gyrA. Importantly, S. Typhi H58 were found 
in many countries in Asia and were becoming more common 
in more recent isolates. The conserved PFGE MDR clade found 
in Vietnam was identified as haplotype H58. S. Typhi H58 fre-
quently harbored MDR plasmids of IncHI1 type.
WHOLE GENOME SEQUENCING OF S. TYPHI
In 2000, the first complete genome sequence of an MDR S. Typhi 
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is not H58, but it does harbor a classical S. Typhi-associated 
transferrable R plasmid named pHCM1. pHCM1 encodes resis-
tance genes for all first-line antibiotics used for the treatment of 
typhoid fever and is highly related to R27, an IncHI1 plasmid 
that was first isolated in the 1960s from S.  enterica. pHCM1 
has acquired additional genes compared to R27, predominantly 
at 2 points with 18 genes encoding resistance to antibiotics 
and heavy metals. Multiple transposon-like and integrases/
transposases are encoded around these 2 regions suggesting a 
recombination hotspot. Antibiotic resistance genes encoded on 
pHCM1 include dhfr1b (trimethoprim), sul2 (sulphonamide), 
catI (chloramphenicol), bla (TEM-1; ampicillin), tetA/tetC 
(tetracyclines), and strAB (streptomycin). Further comparative 
analysis of IncHI1 plasmids showed that these plasmids were 
highly conserved in their broad framework but showed some 
variation at these two recombinatorial hotspots.
With the introduction of next generation sequencing the 
analysis of thousands of S. Typhi at the whole genome level 
rapidly became feasible and currently several thousand S. 
Typhi have been sequenced [18–21]. These data provide an 
enormous expanding database that has been used to define the 
global S. Typhi population structure and to analyze the antibi-
otic resistance signatures of individual isolates and clades. All 
currently circulating S. Typhi have a common ancestor and can 
be regarded as a monophyletic clade that entered the human 
population from an unknown source several thousand years 
ago. MDR isolates can be found around the phylogenetic tree, 
but over 50% of recent isolates belong to clade H58 with a sig-
nificant proportion of these harboring MDR and fluoroquino-
lone resistance alleles [19].
However, clear evolutionary patterns can be detected. S. Typhi 
H58 isolates are widely distributed in Asia and the Middle East 
region. In addition, there have been at least 3 recent indepen-
dent introductions of S. Typhi H58 into the African continent 
that have become established. These 3  “waves” are currently 
still present in Kenya, and the H58 introductions have spread 
across East Africa through several countries including Uganda, 
Tanzania, Zaire, and Malawi. S. Typhi H58 isolates have also 
entered Zimbabwe and South Africa but have not become 
dominant in West Africa. Interestingly, IncHI1 plasmids are not 
always present in newer S. Typhi isolates that express the MDR 
phenotype. Instead, regions of the composite transposon pres-
ent on the IncHI1 plasmids have integrated into the S. Typhi 
chromosome, into at least 2 different genetic loci on multiple 
occasions. This was concerning in that chromosomally inte-
grated DNA tends to be more stable and is less likely to be lost 
compared to a plasmid. Additionally, this highly fluid genetic 
region could act as a hot spot for sampling other genetic mate-
rial taken up from the environment. Fluoroquinolone signature 
mutations are less common in S. Typhi from Africa than Asia, 
More recently a S. Typhi H58 “triple mutant” clade possessing 
2 signature mutations in gyrA (codon 83 and 87) and a third in 
parC (codon 80) has been observed in Nepal as well as India 
and has been associated with a lack of fluoroquiolone efficacy 
[22, 23]. The reduced frequency of these mutations in Africa 
may be a reflection of the use of this class of antibiotics on the 
different continents [19].
Interestingly in West Africa, the evolution of MDR in S. 
Typhi appears to have taken a different path as H58 isolates 
have not become established there [24, 25]. Instead S. Typhi of 
haplotype H56 (3.1.1) that harbor a range of different R factor 
types, including some of IncHI1 type, have become established, 
for example, in Nigeria and Ghana. The genomic evidence indi-
cates that several of these West African MDR clades have spread 
extensively in the region, crossing into multiple countries and 
causing sustained outbreaks. Similar clades have also been 
found in the Republic of Congo suggesting widespread typhoid 
in the region [26].
THE EMERGENCE OF EXTENSIVELY RESISTANT 
S. TYPHI
In 2017, reports emerged of a large outbreak in Sindh, Pakistan, 
of a S. Typhi expressing resistance to classical first-line antibiotics 
(chloramphenicol, ampicillin, and trimethoprim-sulfamethox-
azole), as well as to both fluoroquinolones and third-generation 
cephalosporins. These infections can only be resolved with azi-
thromycin, carbapenems (meropenem) and tigecycline (Table 
1). Because only one of these remaining antibiotics can be 
Table 1. Treatment Options for Different Resistance Classes of S. Typhi
Antibiotic Route of Administration MDR Pakistan XDR
Chloramphenicol Oral, intravenous X X
Co-trimoxazole Oral, intravenous X X
Ampicillin Oral, intramuscular, intravenous X X
Ciprofloxacin Oral, intravenous  X
Ceftriaxone Intramuscular, intravenous  X
Azithromycin Oral   
Meropenem Intravenous   
Tigecycline Intravenous   
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administered orally, this presents a difficult and costly treatment 
practice, which is especially challenging in resource-limited set-
tings. This outbreak stimulated an emergency response involving 
public health management and a typhoid vaccination campaign. 
The isolates were eventually classified as being “extensively drug 
resistant”[XDR] [27, 28]. Whole-genome sequencing of represen-
tative XDR isolates confirmed that this was indeed an outbreak 
involving a highly conserved subclade of the H58 haplotype. 
Subsequent genome analysis showed the clade harbored a very 
large pool of resistance determinants, with the chromosomally 
integrated composite resistance loci and an additional novel IncY 
plasmid encoding a blaCTX-M-15 extended-spectrum β-lactamase 
gene and a qnrS fluoroquinolone resistance gene (Figure 1). 
It is concerning that the blaCTX-M-15 and qnrS are encoded on the 
same plasmid raising the potential that treatment with one of 
the target antibiotic may favor the retention of both genes. The 
Figure 1. Outline genetic structure of XDR S. Typhi in Pakistan. A, Oval outlines represent individual bacteria harboring chromosome (wiggly, green) and plasmid (red and 
blue circles) elements. Red and blue triangles represent acquired resistance loci. Small purple triangles represent SNPs in the chromosome associated with resistance. B, 
Detailed structures with color codes as per A of the different acquired resistance elements on plasmid and chromosome. Abbreviations: AMR, antimicrobial resistance; MDR, 
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IncY plasmid was highly homologous to a similar plasmid group 
reported widely in other enteric bacteria around the globe, sug-
gesting that the IncY plasmid may have been acquired by conjuga-
tion from an E. coli cohabiting the intestine of an individual [27]. 
Further genetic analysis showed that the H58 subclade associated 
with XDR was quite widely spread in Pakistan and other coun-
tries in the Middle East before the IncY plasmid was acquired 
in Sindh. Worryingly, the same XDR S. Typhi clade was isolated 
from a traveler returning from Pakistan to the United Kingdom 
and United States, indicating the clade is capable of interconti-
nental spread [27]. There have been other reports of sporadic 
cases of XDR S. Typhi involving non-H58 isolates and different 
plasmids [28].
WHAT NEXT?
These recent developments involving XDR isolates highlights 
the evolving threat of antibiotic resistance in S. Typhi and the 
value of antibiotic susceptibility testing linked to genomic 
analysis. Thus, we need to develop further low-cost diag-
nostic tools and kits that can be used in the field to rapidly 
detect such strains. Such tools should be linked to an open 
access, global database of whole genome-based sequences of 
S. Typhi. Such databases do exist in various DNA sequence 
repositories, but they are not readily accessible to groups 
or organizations not well trained in the genomic sciences. 
We need to develop simple software that can be used to 
rapidly select diagnostic signatures from these data that 
can be quickly used to modify and update diagnostic tools. 
Isothermal polymerase chain reaction technologies are being 
developed that are relatively inexpensive and can work on 
simple platforms such as dipsticks and these will be vital, 
potentially along with better serological and culture-based 
technologies for typhoid. These diagnostic approaches will be 
used in conjunction with the implementation of better public 
health management approaches including vaccine campaigns 
to bring typhoid under control in endemic regions. However, 
it should be noted that vaccination would likely not specif-
ically target resistant oversensitive isolates, but it would at 
least reduce the overall typhoid disease burden.
Finally, it should be noted that the incidence of MDR in 
typhoid is variable over time. As antibiotic treatment prac-
tices change, the selective pressure profile is altered, and the 
incidence of MDR typhoid has been observed to increase and 
decrease over time in a particular geographical region. This 
suggests that selection is playing a significant role in the main-
tenance of the resistance phenotype and that better antibiotic 
stewardship could have a beneficial impact.
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